Skip To Main Content
Devrim Cabuk on Muck Rack

Devrim Cabuk

As seen in: Nature, JAMA Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Devrim Cabuk’s profile

Articles by Devrim Cabuk

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer : Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

|
By Jingjing Liu, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, HAOYU YU, Jing Li, Xinyi Yang, Qingyu Wang, Jun Zhu, Ahmet Bilici, Aihong Zhong, Alexandre Tavartkiladze, Bangwei Cao, Chun Liang Chen, Davit Giorgadze, Denys Pominchuk, Devrim Cabuk, Dongji Chen, Fedor Moiseenko, Feng Luo, Gaofeng Li, Gongyan Chen, Guangyu An, Guoping Sun, Guosheng Feng, Yanrong Song, Haixin Huang, Hakan Harputluoglu, Hao Xiong, Hui Zhao, Igor Bondarenko, Irfan Cicin, Ivan Sinelnikov, Jian Fang, Jiuwei Cui, Junguo Lu, Kejing Ying, Konstantin Penkov, Liqin Lu, Liyan Jiang, Lu Yue, Mahmut Gümüş, Mehmet Artaç, Mengzhao Wang, Min Fan, Mustafa Özgüroğlu, Peiguo Cao, Peiyan Zhao, Ping Sun, Robert M. Mróz, Sergey Orlov, Shuang Zhang, Shuqun Zhang, Tao Zhang, Tuncay Göksel, Wen Lin, Wenlei Zhuo, Xiaoli Zhu, Xiubao Ren, Yan Wang, Yanping Hu, Yarong Li, Ying Cheng, Yuksel Urun, Zhendong Chen, Zhenyu You, Zhixiong Yang, Zhong Lin, Zhuang Yu, Alev Türker, Amiran Matitashvili, Andrey Akopov, Andrii Gardashnikov, Cagatay Arslan, Eugeny Kulikov, Igor Lifirenko, Ligong Nie, Malgorzata Ulanska, Maria Smagina, Mariam Zhvania, Nadezhda Kovalenko, Oleg Kobziev, Oleksii Kolesnik, Olexandr Goloborodko, Sergey Cheporov, Shenpeng Ying, Tariel Kitiashvili, Timur Andabekov, Tsira Kortua, Vadim Shirinkin, Vladimer Kuchava, Yevhen Hotko, Yuriy Semegen
| JAMA Oncology Verified
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial Key Points Question What are the long-term efficacy and safety outcomes of adding serplulimab to first-line chemotherapy for previously untreated extensive-stage small cell lung cancer (ES-SCLC)?
Open in Who Shared Issue with article?

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

|
By Muhammet Cengiz, Oktay Bozkurt, Ayşe Cengiz, Deniz Can Guven, Elif Tugba Sahin, Elif Ayça Şahin, Mustafa Ersoy, Sedat Yildirim, Beyza Ünlü, Hayati Arvas, Mehmet Mutlu Kidi, Sedat Biter, Mustafa Erman, İsmail Kara, Umut Kefeli, Saadettin Kilickap, Teoman Şakalar, Berrak Mermit Ercek, Havva Yesil Cinkir, Metin Ozkan, Emel Mutlu Ozkan, Ezgi Turkoğlu, Erdem Kolemen, Latif Karahan, Meltem Baykara, Pervin Can Sanci, Anıl Karakayali, Devrim Cabuk, Nargiz Majidova, Muslih Urun, Gözde Agdas, Duygu Bayir, Cengiz Akosman, Erkam Kocaaslan, Mevlude Inanc
| Nature Verified
Abstract Nivolumab is currently widely used in the treatment of lung cancer. Studies have been conducted using flat doses of 240 mg and 3 mg/kg. In fact, studies involving a small number of patients have begun to explore low-dose immunotherapies. The literature on the optimal dose of immunotherapy, the use of weight based, or fixed doses is very recent and has become a one of the subject of ongoing research. This multicenter study included 716 patients with NSCLC.
Open in Who Shared Issue with article?
Show More